Search
                    Minnesota Paid Clinical Trials
A listing of 2107  clinical trials  in Minnesota  actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
            625 - 636 of 2107
        
                Minnesota is currently home to 2107 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Minneapolis, Rochester, Saint Paul and Duluth. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
            
                                                Featured Trial
                
                Healthy Participants Needed (Colonoscopy + Cancer Screening)
            
        Recruiting
            
        Earn $325 - $475 in electronic payment card compensation for your time and effort by participating in a clinical study to develop a blood test that may one day help screen for colon cancer. Take a quick quiz to see if you qualify.
    
    
                            Conditions: 
                                    
        
            
                        Healthy
                    
                                    
                        Healthy Volunteers
                    
                                    
                        Healthy Subjects
                    
                                    
                        Healthy Volunteer
                    
                                    
                        Healthy Participants
                    
                                    Featured Offer
                
                Lose Weight with GLP-1 Medications
            
        Recruiting
            
        Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to semaglutide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®. 
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $50 off your first program with code policy-lab-50.
    GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $50 off your first program with code policy-lab-50.
                            Conditions: 
                                    
        
            
                        Overweight
                    
                                    
                        Overweight and Obesity
                    
                                    
                        Obesity
                    
                                    
                        Weight Loss
                    
                                    
                        Morbid Obesity
                    
                                    Featured Trial
                
                Stroke Clinical Study
            
        Recruiting
            
        A clinical study for people that suffer with Stroke
    
    
                            Conditions: 
                                    
        
            
                        Stroke
                    
                                    Featured Trial
                
                Chronic Kidney Disease (CKD) Clinical Study
            
        Recruiting
            
        A clinical study for people that suffer with Chronic Kidney Disease (CKD)
    
    
                            Conditions: 
                                    
        
            
                        Chronic Kidney Disease (CKD)
                    
                                    Featured Trial
                
                Ischemic heart disease (IHD) Clinical Study
            
        Recruiting
            
        A clinical study for people that suffer with Ischemic heart disease (IHD)
    
    
                            Conditions: 
                                    
        
            
                        Ischemic heart disease (IHD)
                    
                                    
                
                                    Prevention of Ototoxicity in NTM Patients Treated With IV Amikacin
                                
            
            
        Recruiting
                            
            
                The goal of this clinical trial is to test the effectiveness of the study drug, ORC-13361, in preventing hearing loss in patients with NTM infection who are undergoing treatment with IV amikacin therapy. The main question this study aims to answer is:
* Is ORC-13661 effective for preventing or lessening hearing loss induced by amikacin treatment?
* Is ORC-13661 effective for preventing or lessening other measures of hearing impairment?
Participants will be asked to take a study drug while they...  Read More             
        
        
    Gender:
                ALL
            Ages:
                Between 18 years and 80 years
            Trial Updated:
                07/28/2025
            
            Locations: Mayo Clinic, Rochester, Minnesota         
        
        
            Conditions: Ototoxicity, Drug-Induced
        
            
        
    
                
                                    (Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer
                                
            
            
        Recruiting
                            
            
                This open-label research study is studying (Z)-endoxifen as a possible treatment for pre-menopausal women with ER+/HER2- breast cancer. (Z)-endoxifen belongs to a group of drugs called selective estrogen receptor modulators or "SERM", which help block estrogen from attaching to cancer cells. This study has two parts: a pharmacokinetic part and a treatment part.
The PK part (how the body processes the drug) will enroll about 18 participants. All participants will take (Z)-endoxifen capsules dail...  Read More             
        
        
    Gender:
                FEMALE
            Ages:
                18 years and above
            Trial Updated:
                07/28/2025
            
            Locations: Mayo Clinic Rochester, Rochester, Minnesota         
        
        
            Conditions: Breast Neoplasms, Invasive Breast Cancer, Estrogen-receptor-positive Breast Cancer, HER2-negative Breast Cancer
        
            
        
    
                
                                    Cancer Survivor Cardiomyopathy Detection
                                
            
            
        Recruiting
                            
            
                The purpose of this study is to improve the cardiovascular care of adult cancer survivors. The goal is to obtain the data necessary to plan and develop a nation-wide network of a screening program that can help provide cost-effective and long-term monitoring.             
        
        
    Gender:
                ALL
            Ages:
                Between 18 years and 99 years
            Trial Updated:
                07/28/2025
            
            Locations: Mayo Clinic in Rochester, Rochester, Minnesota         
        
        
            Conditions: Cardiovascular Diseases, Cancer
        
            
        
    
                
                                    A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Patients With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
                                
            
            
        Recruiting
                            
            
                This study is researching an experimental drug called linvoseltamab in combination with other drugs for the treatment of a blood cancer called multiple myeloma. Linvoseltamab has previously been studied as a single agent (without other cancer treatments) in participants with multiple myeloma that returned after prior therapies and needed to be treated again.
In the initial study, some participants treated with linvoseltamab had improvement of their myeloma, including complete responses (no evid...  Read More             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                07/28/2025
            
            Locations: Mayo Clinic, Rochester, Minnesota         
        
        
            Conditions: Multiple Myeloma
        
            
        
    
                
                                    Pulmonary Hypertension Association Registry
                                
            
            
        Recruiting
                            
            
                The PHA Registry (PHAR) is a national study about people who have pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH). PHAR collects information from people with PAH and CTEPH who are cared for in participating PHA-accredited Pulmonary Hypertension Care Centers throughout the U.S.
PHAR will determine how people with PAH and CTEPH are evaluated, tested, and treated, and will observe how well these participants do. The goal is to see if people with PH a...  Read More             
        
        
    Gender:
                ALL
            Ages:
                0 years and above
            Trial Updated:
                07/28/2025
            
            Locations: University of Minnesota Health, Minneapolis, Minnesota         
        
        
            Conditions: Pulmonary Arterial Hypertension, Chronic Thromboembolic Pulmonary Hypertension, Pulmonary Hypertension
        
            
        
    
                
                                    Phase 3 Study of PDS0101 and Pembrolizumab in HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
                                
            
            
        Recruiting
                            
            
                This is a global, multi-center, Phase 3 study that is randomized 2:1, controlled, and open label to evaluate PDS0101 (Versamune + HPVMix) in combination with pembrolizumab vs. pembrolizumab monotherapy as first-line treatment in patients with unresectable recurrent or metastatic HPV16-positive HNSCC expressing programmed cell death ligand-1 (PD-L1) with combined positive score (CPS) ≥1.             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                07/25/2025
            
            Locations: Mayo Clinic Rochester, Rochester, Minnesota         
        
        
            Conditions: Recurrent Head and Neck Cancer, Metastatic Head and Neck Cancer, HPV Positive Oropharyngeal Squamous Cell Carcinoma, Neoplasms, Head and Neck, Unresectable Head and Neck Squamous Cell Carcinoma
        
            
        
    
                
                                    A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
                                
            
            
        Recruiting
                            
            
                The purpose of ARTEMIDE-Lung02 is to assess the efficacy and safety of rilvegostomig in combination with platinum-based chemotherapy for the first-line (1L) treatment of patients with metastatic squamous non-small cell lung cancer (mNSCLC) whose tumors express programmed death-ligand 1 (PD-L1).             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                07/25/2025
            
            Locations: Research Site, Duluth, Minnesota         
        
        
            Conditions: Non-small Cell Lung Cancer
        
            
        
    
                
                                    Medical Cannabis in Patients With Advanced Pancreatic and Colorectal Cancer
                                
            
            
        Recruiting
                            
            
                Many patients with advanced pancreatic cancer and colorectal cancer experience burdensome and difficult-to-treat symptoms. The impact of multiple symptoms (called "symptom burden") can negatively affect a patient's quality of life, decrease their ability to tolerate cancer treatments, and lead to worse survival. Current approaches to manage these cancer-associated symptoms often work poorly, with most patients reporting a moderate to severe symptom burden. Therefore, there is an urgent need for...  Read More             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                07/25/2025
            
            Locations: HealthPartners Cancer Research Center, Saint Louis Park, Minnesota         
        
        
            Conditions: Pancreatic Cancer Non-resectable, Pancreatic Cancer Metastatic, Colorectal Cancer Metastatic
        
            
        
    
                
                                    A Study to Learn More About How Well Sevabertinib (BAY 2927088) Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
                                
            
            
        Recruiting
                            
            
                Researchers are looking for a better way to treat people who have advanced non-small cell lung cancer (NSCLC) with specific genetic changes called human epidermal growth factor receptor 2 (HER2) mutations.
Advanced NSCLC is a group of lung cancers that have spread to nearby tissues or to other parts of the body or that are unlikely to be cured or controlled with currently available treatments. HER2 is a protein that helps cells to grow and divide. A damage (also called mutation) to the building...  Read More             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                07/25/2025
            
            Locations: University of Minnesota Medical Center, Minneapolis, Minnesota         
        
        
            Conditions: Advanced Non-small Cell Lung Cancer, HER2 Mutation
        
            
        
    
                
                                    Group Cognitive Behavior Sessions (CBCSM) to Decrease Distress in Cancer Patients
                                
            
            
        Recruiting
                            
            
                This clinical trial tests how well cognitive behavioral cancer stress management (CBCSM) group sessions work to decrease psychological distress in cancer patients. CBCSM teaches patients how to recognize and reduce the impacts of cancer associated stress on the biological, psychological, and social life domains.             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                07/25/2025
            
            Locations: Mayo Clinic in Rochester, Rochester, Minnesota         
        
        
            Conditions: Hematopoietic and Lymphoid System Neoplasm, Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm
        
            
        
    
                
                                    The Actuate-CBC Study
                                
            
            
        Recruiting
                            
            
                The study team will use implementation science to accelerate the uptake of teleconsultationfor burn patients by 1) examining the relationships between clinician perceptions of acceptability, feasibility, intention to use, and actual use of burn teleconsultation 2) identifying the optimal process for burn teleconsultation and the barriers and facilitators for its use during a crisis or prolonged care situation, and 3) designing and testing the effectiveness of a specific, tailored burn teleconsul...  Read More             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                07/25/2025
            
            Locations: Regions Hospital Burn Center, Saint Paul, Minnesota         
        
        
            Conditions: Telemedicine
        
            
        
    
                
                                    Voice Analysis Technology to Detect and Manage Depression and Anxiety in Cardiac Rehabilitation
                                
            
            
        Recruiting
                            
            
                The purpose of this study is to learn if a voice analysis smartphone app which detects anxiety and depression could be used along with cardiac rehabilitation to improve results compared to cardiac rehabilitation alone.             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                07/25/2025
            
            Locations: Mayo Clinic in Rochester, Rochester, Minnesota         
        
        
            Conditions: Myocardial Infarction
        
            
        
    